Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature

• Published in: Frontiers in immunology Vol. 14; p. 1226993
• Main Authors: Zhou, Qihao, Qin, Zhiquan, Yan, Peiyuan, Wang, Qunjiang, Qu, Jing, Chen, Yun
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 06.10.2023
• Subjects: case report; cystitis; immune-related adverse events; Immunology; tislelizumab; ureteritis
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1226993

Immune checkpoint inhibitor (ICI) is an up-to-date therapy for cancer with a promising efficacy, but it may cause unique immune-related adverse events (irAEs). Although irAEs could affect any organ, irAEs-induced whole urinary tract expansion was rarely reported. Herein, we reported a 27-year-old male patient with thymic carcinoma who received the treatment of tislelizumab, paclitaxel albumin and carboplatin. He was hospitalized for severe bellyache and lumbago after 6 courses of treatment. Antibiotic and antispasmodic treatment did not relieve his symptoms. The imaging examinations reported whole urinary tract expansion and cystitis. Therefore, we proposed that the patient’s pain was caused by tislelizumab-induced ureteritis/cystitis. After the discontinuation of tislelizumab and the administration of methylprednisolone, his symptoms were markedly alleviated. Herein, we reported a rare case of ICI-induced ureteritis/cystitis in the treatment of thymic cancer and reviewed other cases of immunotherapy-related cystitis and tislelizumab-related adverse events, which will provide a reference for the diagnosis and treatment of ICI-related irAEs.